Cholangiocarcinoma is a cancer with no distinct early symptoms, making early detection challenging, and its exact pathogenesis remains unclear. In Western countries, it is classified as a rare cancer due to its relatively low incidence, and its symptoms vary depending on the tumor location, further complicating prevention and early diagnosis.
Over the years, many clinical trials for cholangiocarcinoma treatments have faced high failure rates, resulting in a lack of globally established standard therapies for patients with disease progression after first-line chemotherapy. To overcome these challenges and accelerate the development of novel therapeutics for cholangiocarcinoma, establishing a reliable organoid model was essential.
In collaboration with Lambda Biologics, we have successfully established a cholangiocarcinoma organoid model, which we hope will contribute to the development of targeted therapies for cholangiocarcinoma.